Telomir Pharmaceuticals Inc TELO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
-
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
-
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
-
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
Trading Information
- Previous Close Price
- $1.27
- Day Range
- $1.22–1.27
- 52-Week Range
- $1.05–3.10
- Bid/Ask
- $1.21 / $1.25
- Shares Outstanding
- 68.77M
- Market Cap
- $84.59M
- Volume/Avg
- 29,900 / 151,075
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- —
- Website
- https://www.telomirpharma.com
Valuation
|
Metric
|
TELO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.56 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TELO
|
|---|---|
Quick Ratio | 6.72 |
Current Ratio | 7.00 |
Interest Coverage | −7,768.74 |
Quick Ratio
TELO
Profitability
|
Metric
|
TELO
|
|---|---|
Return on Assets (Normalized) | −101.35% |
Return on Equity (Normalized) | −121.87% |
Return on Invested Capital (Normalized) | −126.49% |
Return on Assets
TELO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?<T<y#Y | LOCK|!Ld@ | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|d#>^@? | LOCK|Q>@$V | $70B | |||
| argenx SE ADR
ARGX
| LOCK|Lcn#?# | LOCK|ms | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|g%#%D$ | LOCK|^rL>j | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|xNwZRm | LOCK|!yv | $36B | |||
| Moderna Inc
MRNA
| LOCK|<&@Zbv | LOCK|y% | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|TW>$t%Y | LOCK|?&gP | $25B | |||
| Incyte Corp
INCY
| LOCK|z@fX<d | LOCK|<#^ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|v#%m!W | LOCK|Hb# | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|pkH>>% | LOCK|>C | $17B |
United States